AtaGenix, a leader in biotechnology and therapeutic solutions, is excited to participate in the AACR Annual Meeting 2025, held from April 5–10 in San Diego, California. The event, a premier platform for oncology advancements, will feature AtaGenix’s breakthroughs in Single B cell antibody discovery, advanced antibody engineering, and targeted immunotherapy. Key highlights include cutting-edge technologies for high-affinity antibody development, optimization methods such as humanization and bispecific design, and innovative solutions for precise, personalized cancer therapies. AtaGenix aims to advance the field of oncology with its pioneering approaches to antibody-based treatment and discovery.
